Lundbeck Seizure Drug Poses Serious Skin Risks, FDA Warns

Law360, New York (December 3, 2013, 3:11 PM EST) -- Drugmaker Lundbeck Inc.'s seizure medication Onfi may cause rare but potentially fatal skin reactions including toxic epidermal necrolysis, a condition characterized by the peeling away of skin cells, the U.S. Food and Drug Administration warned Tuesday.

The agency, which said it has approved label changes to alert consumers about these life-threatening skin reactions, said that the reactions could occur any time during the treatment but that patients could be particularly vulnerable to it during the first two months of their treatment, or when they restart the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.